Skip to NavigationSkip to content

New epilepsy drug launches in UK

Published on 29/02/16 at 11:05am

UCB Pharma’s Briviact (brivaracetam) has been authorised as an add-on treatment for partial onset seizures (POS), with or without secondary generalised seizures in adults with epilepsy, offering an additional treatment option for UK patients.

In an international Phase III study of 768 patients uncontrolled on their previous medication, Briviact was shown to give significant seizure freedom over placebo, compared with the patients’ usual medication. Patients also revealed the importance of reducing the titration period – which 51% of patients who participated in an independent European treatment satisfaction survey identified as an important goal.

Dr Mark Manford, consultant neurologist at Bedford and Addenbrookes Hospitals, comments: “Finding the right combination of medicines for many epilepsy patients can be a long journey, during which time the patient may continue to suffer seizures and living a normal life is very difficult.  As a neurologist working with patients whose seizures have not yet been brought under control, I welcome the possibility that a new medicine may be able to contribute to the tools available to help my patients.”

The US FDA recently approved Briviact in this same indication, based on trial data in which the drug, when taken with other medications, was shown to be effective in reducing the frequency of seizures

Joel Levy

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches